Tag Archives: Medical Research

C Diff Foundation Presents Award to CutisPharma in Recognition of Contribution to C. diff. Community

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that it presented CutisPharma, Inc., its "Making a Difference" award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

The award was presented at CutisPharma's celebration of its upcoming launch of FIRVANQ(TM), recently approved by the FDA for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Upon launch, FIRVANQ(TM) will be the only FDA-approved oral vancomycin solution treatment commercially available, improving patient access and reducing pharmacist burden by no longer having to compound oral liquid formulations.

"CutisPharma has been a committed partner of our Foundation and has furthered our mission to increase C.diff. awareness and support the research and development of new treatment options," said Nancy C. Caralla, Foundress and Executive Director of the C Diff Foundation. "In recognition of CutisPharma's efforts, we are pleased to grant them the 'Making a Difference' award at this special moment in the Company's 20th anniversary year."

"We are very grateful to receive such a special distinction from the C Diff Foundation," said Neal I. Muni, MD, MSPH, and Chief Executive Officer of CutisPharma. "For 20 years, we have been committed to improving the lives of patients who are not well-served by existing therapies and would benefit from high-quality, cost-effective new treatment options. We greatly value our partnership with the C Diff Foundation and look forward to continuing to support their mission."

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3)non-profit organization, established in 2012, is comprised of 100 percent volunteering professionals dedicated to supporting public health initiatives for C. difficile infection prevention, treatments, environmental safety, and support worldwide. For more information, visit: https://cdifffoundation.org/.

About CutisPharma:

CutisPharma, Inc., based in Wilmington, Mass., is privately held, specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists. CutisPharma's FIRST(r) Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company's first FDA-approved Kit, FIRVANQ(TM), will allow significantly broader patient access, convenience to pharmacists and patients alike by reducing the need for compounding, and serve as a potential cost-saving option to existing treatments. For more information, visit: https://cutispharma.com/.

The C Diff Foundation today announced that it presented CutisPharma, Inc., its "Making a Difference" award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

Related link: https://cdifffoundation.org/

Neurotech Reports Announces 2018 Investment and Management Conference for Bioelectronic Medicine

NEW YORK, N.Y. /ScoopCloud/ -- Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.

Featured speakers include Gene Civillico, Ph.D., the Program Manager for the National Institute of Health's SPARC program. Also presenting is Eric Van Gieson, Ph.D., Program Manager at DARPA's Biological Technologies Office, which oversees the ElectRx program. These two U.S. government programs have funded much of the early research into bioelectronic medicine.

Sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties. Attendees will hear from some of the leading researchers and entrepreneurs developing clinically and commercially promising products such as implanted vagus nerve stimulation systems to treat hypertension, and surface stimulation devices to treat a range of disorders.

Several early-stage and emerging bioelectronic medicine firms will be presenting at the conference. These include NeuSpera Medical, which is developing a unique mid-field power technology that uses the body as a waveguide to power bioelectronic devices. Also presenting is Axion Biosystems, a manufacturer of multi-well microelectronic electrode arrays, and Neuroelectrics, a Spanish firm that manufactures noninvasive stimulation and recording devices.

The conference is co-sponsored by the Feinstein Institute for Medical Research. Imran Eba of Action Potential Venture Capital, GSK's venture arm in bioelectronic medicine, will serve as a moderator. The event takes place in the same venue and one day prior to the Future Leaders Conference, which is produced and organized by BioCentury, a global leader in business intelligence for the biopharma industry. BioCentury is pleased to serve as a marketing partner of the Bioelectronic Medicine Forum.

"Bioelectronic medicine represents one of the fastest growing segments of the life sciences industry. Participants at the 2018 Bioelectronic Medicine Forum will have an opportunity to help shape the future of this exciting field," said James Cavuoto, editor and Publisher of Neurotech Business Report.

For more information, contact James Cavuoto at 415-546-1259 or visit http://www.neurotechreports.com/pages/bioelectronic-medicine-forum.html .

*PHOTO: Send2Press.com/300dpi/18-0130s2p-Gene-Civillico-300dpi.jpg

Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.

Related link: http://www.neurotechreports.com/

Auto Iron Brake Dust and High Blood Pressure: The ‘Moon Dust’ Link

KESWICK, Va. /ScoopCloud/ -- Did you know that every person has 50,000 miles of blood vessels that are exposed to deadly iron? This is the concept that will be addressed by William J. Rowe, M.D. at the upcoming Internal Medicine and Patient Care Conference, March 26-27, 2018 in Vienna, Austria.

The information he will be presenting was derived from his studies of moon walkers, Neil Armstrong and James Irwin, who brought deadly iron dust into the habitat on their space suits and inhaled it for at least three days until their return to Earth.

His compelling research is further substantiated by new evidence from the lunar landing missions that show dust from car and truck brakes, far from being just unsightly grime on wheels, may be a key factor in the global epidemic of high blood pressure. The findings suggest that inhaling brake dust, spewed into the air around roads, is a health hazard for ordinary people, just as it was for astronauts who landed on the moon.

So, just as astronauts inhaled moon dust (which bears striking similarities to iron brake dust) that clung to their space suits and developed heart problems, people today are inhaling airborne iron brake dust and suffering similar effects.

The latest evidence of this link, perhaps the most significant health lesson from the entire manned space program, appears in a follow-up letter to the editor, "Brake Iron Dust Inhalation Intensifying Hypertension," in the International Journal of Cardiology. It builds on much-overlooked hints, dating to a study in the New England Journal of Medicine, 2004; 351:1721-1730, which linked exposure to road traffic to the onset of a heart attack.

So, what does all this mean to the average person? Dr. Rowe says that people who run or bike outdoors are better off doing it indoors as they age because the risk to the heart is greater with urban pollution caused from iron brake dust.

And, since it has recently been determined by the American Heart Association that half of the U.S. population has hypertension, based on new criteria (130/80), Dr. Rowe believes that information regarding the adverse effects of iron brake dust contributing to hypertension must be promptly and widely disseminated.

"Until legislation is carried out to prevent iron brakes from being manufactured or until effective seals are made, we must offset the adverse effects which triggered the cardiovascular complications, particularly the severe hypertension of the moon walkers," Dr. Rowe says. "A high magnesium diet and well absorbed Mg supplements are warranted to reduce the iron's toxicity."

A colleague of Dr. Rowe's who read his first paper on the hazards of brake iron dust, said, "This is the clearest and most compelling explanation of an environmental hazard that I can recall."

Previously, Dr. Rowe has presented this concept at the Innovate Biotech 2017 conference in Brisbane, Australia and will also be presenting at the 10th Annual International Congress of Cardiology-2018 on November 28-30, 2018, in Rome, Italy.

For more information, visit: http://www.femsinspace.com/

Did you know that every person has 50,000 miles of blood vessels that are exposed to deadly iron? This is the concept that will be addressed by William J. Rowe, M.D. at the upcoming Internal Medicine and Patient Care Conference, March 26-27, 2018 in Vienna, Austria.

Related link: http://www.femsinspace.com/

The C Diff Foundation Raises Clostridium difficile Infection (C.difficile) Clinical Trial Awareness Worldwide

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridium difficile infection (C.difficile) clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

"Clostridium difficile infections are not only the most common cause of healthcare-acquired infections in the United States but also very common in the community in younger patients who previously were thought to be less susceptible to C. difficile. The rate of recurrent C. difficile infections is increasing tremendously and this increase is higher than the rate of primary C. difficile infections," stated Sahil Khanna, MD, Assistant Professor of Medicine Division of Gastroenterology and Hepatology, Director of the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials, Mayo Clinic, Rochester, MN.

Dr. Khanna also added, "It is imperative and important for clinical trials to be done to advance the development of new treatments, new medications, and new ways to prevent and treat Clostridium difficile infections."

Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.

To learn more about clinical research (e.g., Clostridium difficile, C.difficile) visit the U.S. Food and Drug Administration www.fda.gov or telephone 1-800-835-4709, The National Institutes of Health (NIH) www.nih.gov and ClinicalTrials.gov.

"Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections," stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.

About the U.S. Food and Drug Administration (FDA):
The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.

About the National Institutes of Health (NIH):
The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation's medical research agency making important discoveries that improve health and save lives.

About ClinicalTrials.gov
ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)3 non-profit, founded in 2012 with a global mission of providing education for Clostridium difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For information please visit https://cdifffoundation.org/.

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness in 2018 of Clostridium difficile infection (C.difficile) clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Related link: https://cdifffoundation.org/

U.S. Governors Are Applauded for Proclaiming November Clostridium difficile (C.difficile, C.diff.) Infection Awareness Month

BALTIMORE, Md. /ScoopCloud/ -- Many U.S. Governors have signed a state proclamation proclaiming November 2017 as Clostridium difficile (C.difficile, C.diff.) Infection Awareness Month, the non-profit C Diff Foundation announced today.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually.

In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

As a leading health care and patient advocacy organization the C Diff Foundation provides resources concerning C. difficile infection prevention, treatments, environmental safety, and support worldwide.

The C Diff Foundation continues to heighten the urgency of this life-threatening infection with government agencies, academia topic experts, and health care professionals worldwide.

"Our shared goal is to witness a significant reduction in C. difficile infections worldwide by the year 2020. We would also like to thank Rebiotix for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

Through the State Proclamations Clostridium difficile (C.difficile, C.diff.) infection awareness has risen significantly worldwide.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100-percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Visit https://cdifffoundation.org/.

MEDIA CONTACT:
Denise Graham
telephone: 919-201-1512
denise@cdifffoundation.org

Many U.S. Governors have signed a state proclamation proclaiming November 2017 as Clostridium difficile (C.difficile, C.diff.) Infection Awareness Month, the non-profit C Diff Foundation announced today.

Related link: https://cdifffoundation.org/

Inaugural Global C. diff. Walk to raise awareness on importance of Clostridium difficile infection prevention and provide resources

NEW PORT RICHEY, Fla. /ScoopCloud/ -- Presented by the C Diff Foundation, the 1st Annual Global C.diff. Awareness 2K Walk will take place on Saturday, November 4 at Frances Park, New Port Richey, Florida. This event will include refreshments, hydration stations, and resourceful educational material and displays.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The Global C. diff. Walk seeks to raise awareness of Clostridium difficile (C. diff.) infection prevention and provide educational material while introducing the community to the resources available. C.diff. infections are one of the leading health issues facing local communities.

"Every day the C Diff Foundation works to educate and advocate for C. difficile infection prevention, treatments, environmental safety and support worldwide to save lives. Our dedicated volunteering members and patient advocates work to improve the lives of individuals and families that are impacted by a C.diff. infection," says Nancy Caralla, Board President of the C Diff Foundation.

We sincerely thank the following Sponsor for their continued support and for joining the C Diff Foundation in promoting C. diff. Awareness worldwide: Diamond: Seres Therapeutics.

Event Details:
Saturday, November 4, 2017. Registration and Check-in takes place at 8 a.m. Walk and Program begins at 9 a.m. at Frances Park, 5580 Frances Avenue, New Port Richey, Florida 34653.

Registration: https://cdifffoundation.org/.

Walkers can register individually ($5 per person) or as a team ($15 per team) and can recruit sponsors.

All funds raised will support the work of the C Diff Foundation that provide villages to cities with C. difficile infection education, advocacy, and support worldwide.

For additional information about the walk, email info@cdifffoundation.org or call (919)-201-1512.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

*IMAGE: Send2Press.com/300dpi/17-1003s2p-cdiff2k-flier-300dpi.jpg

Presented by the C Diff Foundation, the 1st Annual Global C.diff. Awareness 2K Walk will take place on Saturday, November 4 at Frances Park, New Port Richey, Florida. This event will include refreshments, hydration stations, and resourceful educational material and displays.

Related link: https://cdifffoundation.org/

C Diff Foundation Knocks on Governor’s Doors Nationwide to Proclaim the Month of November for Clostridium difficile Infection Awareness

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation welcomes November as Clostridium difficile Awareness Month and it is an exciting time for patients, families, clinicians, and organizations. Governors in several states honor our efforts by signing proclamations declaring November to be Clostridium difficile Awareness Month in their states.

These proclamations are available to you and can be downloaded for your use from our website: https://cdifffoundation.org/make-a-difference-november/.

This year, our goal is to obtain proclamations in all 50 states. Denise Graham, Strategic Advisor of the C Diff Foundation, proudly leads the Clostridium difficile (C. diff., C. difficile) State Proclamation effort.

Join us at the upcoming 5th Annual International C.diff. Awareness Conference and Health EXPO, taking place on November 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion, Las Vegas, Nevada.

Complimentary registrations are available: https://cdifffoundation.org/registration/

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Dale Gerding, MD, FACP, FIDSA joins 25+ internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) and prevention, treatments, diagnostics, research, clinical trials, with Microbiome research, Infection Prevention, Irritable Bowel Syndrome treatments and clinical trials, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship and more.

To learn more about the program and guest speakers: https://cdifffoundation.org/cdiff2017guest-speakers/

Attendee Linda Jablonski, RN, BSN said about the 2016 conference, "The information shared at the conference provided up-to-date studies and important information that help us all save lives."

Visit https://cdifffoundation.org for more information. Contact Denise Graham for registration and media inquiries desinse@cdifffoundation.org or Mobile (202)-294-6314.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

Media Contact:
Denise Graham
denise@cdifffoundation.org

*IMAGE for media: Send2Press.com/300dpi/17-0928s2p-cdiff-awareness-300dpi.jpg

C Diff Foundation welcomes November as Clostridium difficile Awareness Month and it is an exciting time for patients, families, clinicians, and organizations. Governors in several states honor our efforts by signing proclamations declaring November to be Clostridium difficile Awareness Month in their states.

Related link: https://cdifffoundation.org/

Critical Healthcare-acquired Infections Expo comes to Las Vegas to Address C.difficile Concerns and Patient Risks

LAS VEGAS, Nev. /ScoopCloud/ -- LAS VEGAS, Nev., Aug. 16, 2017 (SEND2PRESS NEWSWIRE) -- C Diff Foundation welcomes Dale Gerding, MD, FACP, FIDSA, and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital as Conference Chair of the upcoming 5th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on November 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Dale Gerding, MD, FACP, FIDSA joins 25+ internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) and prevention, treatments, diagnostics, research, clinical trials, with Microbiome research, Infection Prevention, Irritable Bowel Syndrome treatments and clinical trials, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship and more.

To learn more about the program and guest speakers: https://cdifffoundation.org/cdiff2017guest-speakers/

All attendees will have the highest levels of peer networking and learning opportunity at the International C.diff. Awareness Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting at the health expo.

Attendee Linda Jablonski, RN, BSN said about the 2016 conference, "The information shared at the conference provided up-to-date studies and important information that help us all save lives."

We sincerely thank the following Sponsors for their continued support and for joining the C Diff Foundation in promoting C. diff. Awareness worldwide:
- Diamond: Synthetic Biologics.
- Gold: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Nestle Health Science, Xenex.
- Silver: SporeGen, Tru-D, Pfizer, Environmental Disinfection Management, Surfacide.
- Conference Shuttles Sponsored by Sterilize RD (tm) RAPID UVC DISINFECTOR.

We would also like to thank the following organizations:
* This conference is supported through an educational grant from Sanofi Pasteur US.
* This activity has been supported by an independent patient advocacy grant from Merck & Co., Inc.

Visit https://cdifffoundation.org for more information. Contact Denise Graham for registration and media inquiries denise@cdifffoundation.org or Mobile (202)-294-6314.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100 percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

*LOGO for media: Send2Press.com/300dpi/17-0816s2p-2017CdiffConfLogo-300dpi.jpg

The C Diff Foundation welcomes Dale Gerding, MD, FACP, FIDSA, and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital as Conference Chair of the upcoming 5th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on Nov. 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion.

Related link: https://cdifffoundation.org/

Clifford McDonald, MD and Alison Laufer-Halpin, Ph.D., of the CDC Discuss the Human Microbiome on C. diff. Spores and More

ATLANTA, Ga. /ScoopCloud/ -- C Diff Foundation's "C. diff. Spores and More Global Broadcasting Network" is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on July 25, 2017 at 10 a.m. PT / 1 p.m. ET on C Diff Radio (www.cdiffradio.com).

These leading topic experts will be discussing significant ways to unlock the mysteries of the human microbiome; how it affects our health, the immune system, and why it is so important to protect it.

As part of the Centers for Disease Control and Prevention (CDC) efforts to protect patients and slow antibiotic-resistance, the CDC is investing in research to discover and develop new ways to prevent antibiotic-resistant infections.

Learn more about C Diff Radio at: http://www.cdiffradio.com/.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own journey and the loss of their father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For information please visit https://cdifffoundation.org/.

More information and media queries: info@cdifffoundation.org

C Diff Foundation's "C. diff. Spores and More Global Broadcasting Network" is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on July 25, 2017 at 10 a.m. PT / 1 p.m. ET on C Diff Radio.

Related link: https://cdifffoundation.org/

Nationally Renowned Research Doctor Will Discuss His New Hopes, Methods, and Successes with Treating Rare Children’s Cancers on Nov. 5, 2017

LAKE FOREST, Calif. /ScoopCloud/ -- Jareds Juggernaut To Cure Sarcoma, a non-profit which funds researchers of body sparing cancer treatments targeted for rare children's cancers, today announced an event which features Dr. Charles Keller as the keynote speaker, which will take place on November 5, 2017 in the Sun and Sail Club in Lake Forest, Calif.

While many types of cancers have had improved survival outcomes over recent years due to new drugs and other clinical innovations, there are certain cancers that have not progressed appreciably in their survival rates or in developing new methodologies and drug protocols for decades.

Unfortunately, these cancers primarily affect children and young adults. Since the number of patients diagnosed with these deadly diseases annually is small, compared with other types of cancers, such as breast, prostate and colon, they are treated as "orphan" diseases which translate into less emphasis by the drug companies and medical establishment in finding treatments and cures for these forms of cancer.

It is therefore left to dedicated researchers and grass roots support groups to "pick up the slack" and help those kids afflicted with these deadly diseases by finding new drug protocols and techniques to stop the cancers from metastasizing at worst or to stop the cancer cells from developing at best.

Dr. Charles Keller founded the Children's Cancer Therapy Development Institute in Oregon to bridge scientific discovery and the initiation of clinical trials.

Charles's research focuses on the development of more effective, less toxic therapies for childhood cancers. His special interest is advanced disease that has spread beyond the initial location of the cancer. Charles co-chairs the brain tumor developmental therapeutics committee (CNS-DVL) of the Children's Oncology Group and is a member of the soft tissue sarcoma (STS) committee of Children's Oncology Group.

He recently completed a 5-year rotation as a Standing Member of the National Cancer Institute NCI-I Study Section. Charles has authored over 80 scientific publications and is a recognized expert in the biology of childhood sarcomas and the preclinical investigation of childhood cancers. Charles is also a co-founder of First Ascent Biomedical, a company developing personalized medical approaches to therapy for canine and human solid tumor patients.

Dr. Keller will be speaking on November 5, 2017 at the Sun and Sail Club on Lake Forest Drive in Lake Forest California. He will be discussing his research objectives and some of the resultant outcomes and successes. His keynote speech will be part of an event that will go from 12 p.m. to 4 p.m. Entertainment and refreshments will be available as well as dancing will be encouraged.

The cost for the event is $28 per person with all proceeds going to cancer research. Since the sponsor is a non-profit 501(c)(3), the ticket price will be tax deductible.

To register for this event or for further information call (949)472-4278, or go to following link to RSVP http://www.signupgenius.com/go/5080e4da5a629a2fe3-thespacexinspired

About Jareds Juggernaut To Cure Sarcoma (JJCUR):

JJCUR is a 501(c)(3) non-profit which was started after the founders' 26 year old son, Jared Steven Grossman, died after fighting Rhabdomyosarcoma for five years. The protocol that Jared was given was one that was in place for twenty years and had a less than 20 percent survival rate for his stage of the disease. We found that the chemo and radiation was almost as devastating to Jared's body as the cancer itself and, after he died, we vowed that we would work hard to support researchers who were innovative and looked for body sparing methods to fight cancers.

To learn more log on to: http://www.jaredsjuggernaut.org/.

Jareds Juggernaut To Cure Sarcoma, a non-profit which funds researchers of body sparing cancer treatments targeted for rare children's cancers, today announced an event which features Dr. Charles Keller as the keynote speaker, which will take place on November 5, 2017 in the Sun and Sail Club in Lake Forest, Calif.

Related link: http://jaredsjuggernaut.org/

C Diff Foundation Announces Scholarship Program to Support Health Care Students

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.

To apply for a C Diff Foundation; Michael and Helen Caralla, Sr. Educational Scholarship, the applicant must submit an application by May 1 of each calendar year. The C Diff Foundation selection committee chooses application recipients based on a submitted essay, letters of recommendation, a willingness to complete the Volunteer Service project to promote C. difficile infection awareness requirement, and financial need.

Awards consist of annual scholarships that range in value from $750 to $1,500 USD. Recipients must reapply each year they attend post-secondary school and will be chosen based on their academic progress and mentoring performance.

To be eligible for a Michael and Helen Caralla, Sr. Educational Scholarship the applicant must be:
* A student and a high school graduate or have a General Educational Development a.k.a. General Educational Diploma (GED).
* Enrolled full-time at an accredited post-secondary educational institution during the 2017-2018 academic year (If a foreign student is applying and is chosen, the educational scholarship awarded amount will be converted from USD to the educational institute location foreign currency exchange rate and rounded up to the nearest whole dollar).
* Maintain full-time status throughout the 2017-2018 academic year in order to remain eligible.
* Willing to complete a minimum of 50 volunteer hours promoting C. difficile infection prevention, treatments, and environmental safety awareness in their local communities per academic year awarded the educational scholarship.

C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.

"When you apply to become a C Diff Foundation Scholar, you are taking the first step to determine your own future. The C Diff Foundation Scholars are individuals motivated and dedicated to making a difference in the health care community. We are excited to offer a scholarship program to help support health care students to advance their career path through the Michael and Helen Caralla, Sr. educational scholarship, a program in memory of our loving parents," states Nancy C Caralla, Executive Director.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own CDI journeys and witnessing the passing of her father, diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For additional Scholar Applicant information, visit the C Diff Foundation website: https://cdifffoundation.org/scholarship-eligibility/

Media Coordinator:
Denise Graham, RN, CIC
info@cdifffoundation.org

Twitter: @cdiffFoundation #CdiffScholar

*PHOTO for media: Send2Press.com/mediaboom/17-0711s2p-caralla-300dpi.jpg
*Photo Caption: Michael and Helen Caralla, Sr.

The C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.

Related link: https://cdifffoundation.org/

Chef Sean Brock Honored by Myasthenia Gravis Foundation of America for Awareness Efforts

NEW YORK, N.Y. /ScoopCloud/ -- The Myasthenia Gravis Foundation of America (MGFA), the nonprofit dedicated to raising research funds for and awareness of the neuromuscular disease myasthenia gravis (MG), announces that Chef Sean Brock has graciously volunteered to be an Awareness Ambassador for the organization.

The highly acclaimed chef, most known for his Southern culinary creations and his work on The Mind of a Chef, has spoken out about the challenges he faced in getting diagnosed and managing MG, and has begun planning a series of exclusive dinners aimed at raising funds for the MGFA's mission.

"I clearly had the symptoms of MG, yet it took some of the best doctors in the world 18 months to confirm my diagnosis, and there's no cure," said Brock. "Unless we can fund research that can lead to a cure, we, myself and others with MG, continue to manage the symptoms in the best way that we can."

Brock experienced double vision that made it difficult to walk and impossible for him to drive, and this weakness of his eyes also caused one eyelid to droop so it was nearly closed while the other became stuck wide open. This was not only uncomfortable for dealings with customers, but also made it painful to be in the sunlight, and contributed to further vision issues. While a drooping eyelid is among the classic symptoms of the disease, Brock was among the 10 - 20 percent of patients who have the disease but test negative for MG in bloodwork, making it a challenge for physicians to diagnose.

Brock responded well to treatment, a clear sign that he truly has MG, but fears that his condition could one day worsen, and hopes that research will be ahead of his MG.

"MG is a very challenging condition because of the profound impact it can have on muscle strength and daily activities that most of us take for granted. It is particularly hard to have a disease most people have never heard of -- and for which there is no cure," shared Nancy Law, chief executive officer, MGFA. "We applaud Chef Brock for giving a voice to other patients with MG who have experienced similar frustrations and barriers to diagnosis."

Chef Brock will continue to share his experiences, and more information about his fundraising efforts will be available on http://www.myasthenia.org/ in the coming months.

About Myasthenia Gravis (MG):
Myasthenia gravis is a disorder causing extreme muscle weakness that can impact a person's ability to see, eat, walk - and even to breathe or to smile. The condition is rare and non-contagious, and affects people of all races, genders and ages. In MG, the body's immune system attacks the connection between the nerves and the muscles, which limits the ability of the brain to control muscle movement.

The degree of muscle weakness can vary from person to person, and day to day. Due to the high number of misdiagnoses, the precise number of people with MG is unknown, but MG is estimated to affect approximately 100,000 Americans. There are effective treatments for most, but not all with MG. There is currently no cure.

About The Myasthenia Gravis Foundation of America:
Founded in 1952, the Myasthenia Gravis Foundation of America (MGFA) is the only national volunteer health agency dedicated solely to the fight against the debilitating disease, myasthenia gravis. MGFA is committed to finding a cure for myasthenia gravis and closely related diseases, improving treatment options and providing information and support to people with myasthenia gravis through research, education, community programs and advocacy. MGFA serves patients, their families and caregivers through support groups and educational programs.

For more information, please visit http://www.myasthenia.org/.

*PHOTO for media: Send2Press.com/mediaboom/17-0606s2p-ChefSeanBrock-300dpi.jpg
*Photo Caption: Chef Sean Brock Honored by Myasthenia Gravis Foundation of America for Awareness Efforts.

The Myasthenia Gravis Foundation of America (MGFA), the nonprofit dedicated to raising research funds for and awareness of the neuromuscular disease myasthenia gravis (MG), announces that Chef Sean Brock has graciously volunteered to be an Awareness Ambassador for the organization.

‘C. diff. Science’ Honors Professionals Dedicated to Clostridium difficile Research and Development

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation hosts "C. diff. Science" on Sept. 14 to honor professionals dedicated to the scientific research and development in the Clostridium difficile (C. difficile, C. diff.) community worldwide, chaired by Professor Simon M. Cutting, PhD, of Molecular Microbiology at Royal Holloway, University of London.

The free live webinar will take place from 8 a.m. - 12 p.m. ET, Sept. 14, 2017.

Professor Cutting, Event Chair and guest presenter, shares the platform with seven fellow scientists focused on their contributions involving the most common pathogen identified, and leading healthcare-associated infection (HAI) - Clostridium difficile.

C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.

"On September 14th fellow professionals in the C. diff. community, and those who share a common interest, will have the opportunity to gain knowledge from scientists around the globe who have dedicated their professional lives researching and developing new concepts, new theories, and the progress towards a better understanding - pursuing future developments in Clostridium difficile (a.k.a., C. difficile, C.diff.) infection prevention, treatments, and environmental safety products worldwide," states Nancy C Caralla, Executive Director.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own journeys and witnessing the passing of her father diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For webinar information contact event coordinators: info@cdiffscience.org and visit the event website: http://cdiffscience.org/ to register for this free webinar.

For C Diff Foundation information please visit: https://cdifffoundation.org/.

Media Contact Person:
Nancy Caralla
ncaralla@cdifffoundation.org

*LOGO: https://cdifffoundation.files.wordpress.com/2013/06/cdifflogoadjdtrd.jpg

Twitter: @cdiffFoundation #CDiffScience

The C Diff Foundation hosts "C. diff. Science" on Sept. 14 to honor professionals dedicated to the scientific research and development in the Clostridium difficile (C. difficile, C. diff.) community worldwide, chaired by Professor Simon M. Cutting, PhD, of Molecular Microbiology at Royal Holloway, University of London.

Gastric Cancer Foundation Awards Second Funded Scholar to Accelerate Stomach Cancer Research

SAN FRANCISCO, Calif. /ScoopCloud/ -- Jose Saenz, MD, PhD, of Washington University School of Medicine was named the American Gastroenterological Association (AGA) Research Foundation-Gastric Cancer Foundation latest Research Scholar in Gastric Cancer.

The AGA Research Award Program identifies and supports talented investigators who are pursuing careers in digestive disease research. In 2013, the Gastric Cancer Foundation initiated the first gastric cancer award in collaboration with AGA to encourage talented young investigators to focus on stomach cancer, the most under-funded major cancer.

This award is a $270,000 three-year research grant to support innovative research in gastric cancer, and ensures that a major proportion of the recipient's time is protected for research.

"The Foundation is enormously proud to be able to fund promising young researchers who are working on new discoveries to improve the lives of gastric cancer patients," said Wayne Feinstein, Board Chair of the Gastric Cancer Foundation. "Without this kind of seed money, these young researchers would not be able to seek larger grants to pursue important basic research."

Dr. Saenz's winning project is the study of "Alterations in the Gastric Landscape and the Effects on Helicobacter Pylori Pathogenesis." Helicobacter pylori is a common bacterium, and infects approximately 50 percent of the world's population and is the cause of several gastrointestinal diseases.

"I am honored to have received this award and equally honored to receive your words of encouragement," said Dr. Saenz after being notified by Feinstein.

The first Research Scholar recipient was recently selected to receive Congressional funding through the Department of Defense to continue investigating "Targeting B Cell-Mediated Type II Autoimmunity in Gastric Carcinogenesis," initiated with the Foundation's support.

For more information visit: http://www.gastriccancer.org/.

Like GastricCancerFoundation on Facebook: https://www.facebook.com/GastricCancerFoundation

Follow us on Twitter @GastricCancerFD - https://twitter.com/GastricCancerFD

Check out our videos on YouTube: https://www.youtube.com/channel/UC6Bw6-d6VB49dPzb1Zn8VIQ

Join GCF on LinkedIn: https://www.linkedin.com/company/gastric-cancer-foundation.

ABOUT THE GASTRIC CANCER FOUNDATION & RESEARCH SCHOLAR AWARD:
The Gastric Cancer Foundation is dedicated to improving the lives of people affected by stomach cancer by working with leading researchers to initiate research in pursuit of a cure. The Foundation has granted over $2 million for research.

The Foundation and AGA Research Foundation - http://www.gastro.org/foundation/ - joined together to provide perpetual funding for this award. Each organization committed $1,125,000 in order to establish an endowment of $2,250,000. This assures that funding will be available for young investigators who are researching the fundamental pathobiology of gastric cancer.

MEDIA CONTACT:
Maureen Barry
Of The Gastric Cancer Foundation
415-572-6646
info@gastriccancer.org

*LOGO for media: Send2Press.com/mediaboom/17-0501s2p-gcfounda-300dpi.jpg

Jose Saenz, MD, PhD, of Washington University School of Medicine was named the American Gastroenterological Association (AGA) Research Foundation-Gastric Cancer Foundation latest Research Scholar in Gastric Cancer. The AGA Research Award Program identifies and supports talented investigators who are pursuing careers in digestive disease research.

San Francisco City Hall will be Lit Up Red to recognize World Hemophilia Day

SAN FRANCISCO, Calif. /ScoopCloud/ -- The Hemophilia Foundation of Northern California (HFNC) will participate in World Federation of Hemophilia's (WFH) "Lighting It Up Red!" campaign in recognition of World Hemophilia Day.

On April 17, at 7:30 p.m. on the steps of San Francisco City Hall, HFNC, and the National Hemophilia Foundation (NHF), and families and friends affected by bleeding disorders will gather to celebrate as City Hall is illuminated in red to show support for the millions of people around the world living with a bleeding disorder. HFNC is asking all who wish to show support to join them on the steps of City Hall and to wear red in support of the cause.

World Hemophilia Day is an opportunity to raise awareness of people living with hemophilia and other inheritable bleeding disorders around the world. The "Lighting It Up Red!" campaign seeks to create a visual reminder of the global bleeding disorders community as well as the organizations such as HFNC, who provide support for local individuals and families affected by bleeding disorders.

About bleeding disorders:
Bleeding disorders, a group of disorders that share the inability to form a proper blood clot, include hemophilia, von Willebrand disease (VWD) and rare factor disorders. They are characterized by extended bleeding after injury, surgery, trauma or menstruation. Improper clotting can be caused by defects in blood components such as platelets and/or clotting proteins, also called clotting factors. Currently there are no cures for bleeding disorders and treatment for these conditions varies, depending on their severity. Worldwide, nearly 70 percent of people affected by bleeding disorders have no access to treatment.

About Hemophilia of Northern California:
The Hemophilia Foundation of Northern California provides advocacy, support and resources to more than 3,000 Northern California families with a myriad of inherited and acquired blood related conditions, including life-threatening blood disorders, factor deficiencies and rare clotting conditions.

More information: http://hemofoundation.org/.

MEDIA CONTACTS:
Marion A. Koerper, M.D., Medical Advisor, National Hemophilia Foundation marionkoerper@sbcglobal.net

Patrick Dunlap, Executive Director, Hemophilia Foundation of Northern California
patrick.dunlap@hemofoundation.org
510-658-3324 HFNC office

The Hemophilia Foundation of Northern California (HFNC) will participate in World Federation of Hemophilia's (WFH) "Lighting It Up Red!" campaign in recognition of World Hemophilia Day, on April 17, at 7:30 p.m. on the steps of San Francisco City Hall.

Thirty-Seven U.S. State Proclamations Raise Awareness of Mysterious Childhood Deaths

CEDAR GROVE, N.J. /ScoopCloud/ -- The emotional trauma associated with losing a child is overwhelming. But when that loss is combined with a total lack of explanation, grief can become far more complicated, says the SUDC Foundation. Sudden Unexplained Death in Childhood (SUDC) is the sudden unexplained death of a child over the age of one which remains unexplained after a thorough case investigation is conducted.

It is not a diagnosis but a category of death that eludes our scientific understanding today. In 2015, the U.S. Centers for Disease Control and Prevention reported that 393 children between the ages of 1 and 19 years died without a clear explanation for their death. The majority of SUDC deaths affect children aged 1-4 years.

"It is a frightening statistic, especially since SUDC often occurs in otherwise healthy children during sleep-time," explained Laura Crandall, co-founder and President of the SUDC Foundation, which is dedicated to increasing awareness, funding crucial research and the prevention of SUDC.

The Foundation is the only organization worldwide devoted solely to the needs of families and professionals affected by childhood sudden death.

When Devon and Georgia Boswell lost their precious son Drew on March 12, 2014, at the age of 15 months, they were devastated. "When we lost Drew, we felt all our dreams for the future slip through our fingers. How could our healthy 15 month-old, simply not wake up," a question Georgia Boswell still asks today.

Their friend, Christina Grantham, was also shocked by the inexplicable death of little Drew. She joined forces with the SUDC Foundation to improve the country's awareness of this little known tragedy. In 2016, she spearheaded the first nationwide awareness campaign in the U.S. to proclaim SUDC Awareness month to educate the public and raise funds for crucial research. Twenty-six U.S. states signed on.

"It has been an honor to work with Christina Grantham - a tireless volunteer in the fight to understand and prevent SUDC. Her dedication is not only a reflection of her love for Drew, but also her love for all children," states Lorri Caffrey, Co-founder of the SUDC Foundation.

In 2017, with the coordinated efforts of Christina and bereaved parents across the U.S., the campaign continues to grow. To date, thirty-seven (37) U.S. State Legislatures have issued proclamations that March 2017 is SUDC Awareness Month.

"Awareness is a catalyst that can allow the SUDC Foundation to reach more families and help achieve the end goal of a world without sudden unexplained death in childhood. As Drew's Mother, I could not be prouder that his short life and the passion of Christina Grantham, and so many others, have led to success of SUDC awareness month. This initiative is not just for Drew, it is for all SUDC children. Their legacies continue to bring out the best in people each and every day," says Georgia Boswell.

For more information and to view all of the SUDC US State proclamations visit the SUDC Foundation Website at: https://sudc.org/.

About the SUDC Foundation:

The SUDC Foundation is devoted solely to the needs of professionals and families touched by the unexpected death of a child aged 12 months or older. Since its inception, the non-profit Foundation has funded crucial research, helped hundreds of families in over 16 countries, and led many advocacy efforts, including the successful passage of the Sudden Unexpected Death Data Enhancement and Awareness Act, which was signed into law by President Obama in December 2014. For more information, visit https://sudc.org/ and follow us on Twitter @SUDC.

Video (Vimeo), "Explaining the Unexplained":
https://vimeo.com/196286865

The emotional trauma associated with losing a child is overwhelming. But when that loss is combined with a total lack of explanation, grief can become far more complicated, says the SUDC Foundation. Sudden Unexplained Death in Childhood (SUDC) is the sudden unexplained death of a child over the age of one which remains unexplained after a thorough case investigation is conducted.

No Stomach For Cancer Hosts Stomach Cancer Awareness Event at Fred Hutchinson Cancer Research Center

SEATTLE, Wash. /ScoopCloud/ -- No Stomach For Cancer, an international advocacy organization for stomach cancer, will host its fourth "Spotlight on Gastric Cancer" on Friday, May 12 at the Fred Hutchinson Cancer Research Center's Pelton Auditorium in Seattle, Wash.

Stomach cancer is currently the third leading cause of cancer deaths, worldwide, with one million new cases diagnosed each year. As a result, any opportunity to learn more about medical advancements and research is a step in the right direction.

The "Spotlight on Gastric Cancer" event presents the ideal platform for those in the stomach cancer community, the medical community and the public to come together to learn more about gastric cancer. For example, what is the history of gastric cancer? What is its current state and what are future hopes? Expert researchers, patients and caregivers will share stories and educate each other about current treatment options for gastric cancer and much more.

The event is free and open to the public. The program runs from 9 a.m. to 2 p.m. and registration can be done online here: 2017 Spotlight on Gastric Cancer - http://www.fredhutch.org/en/events/spotlight-gastric-cancer.html.

"Spotlight on Gastric Cancer" participants are also invited to attend a special Night of Healing following the event at the Courtyard Seattle Downtown/Lake Union at 6:30 p.m.

About No Stomach For Cancer:
No Stomach For Cancer, Inc. (NSFC) is a 501(c)(3) nonprofit organization that has a mission to support research and unite the caring power of people, worldwide, who are affected by stomach cancer. Headquartered in Wisconsin, and serving patients across the globe, the organization is a thought leader in stomach cancer awareness and education.

NSFC advances awareness and education about stomach cancer, including Hereditary Diffuse Gastric Cancer (HDGC), provides a support network for affected families, and supports research for screening, early detection, treatment and prevention of stomach cancer.

For more information, visit: https://www.nostomachforcancer.org/.

*LOGO for media: Send2Press.com/mediaboom/17-0321s2p-no-stomach-cancer-300dpi.jpg

Media Contact:
Jon Florin, Executive Director
of No Stomach For Cancer
+1-608-692-5141
jflorin@nostomachforcancer.org

No Stomach For Cancer, an international advocacy organization for stomach cancer, will host its fourth "Spotlight on Gastric Cancer" on Friday, May 12 at the Fred Hutchinson Cancer Research Center's Pelton Auditorium in Seattle, Wash.

The Everest Foundation Launches Initiative with Mount Sinai Medical Center

LOS ANGELES, Calif. /ScoopCloud/ -- The Everest Foundation ("EF"), a non-profit 501(c)(3) located in Los Angeles, California that is nationally focused on the advancement of medical research, has partnered with Mount Sinai Medical Center ("MSMC") in Miami, Florida in a recent initiative to assist with research funding and Graduate Medical Education ("GME") support.

This recent Everest Scholar initiative will help MSMC grow their research and GME residency training program with additional funding. EF looks forward to advancing and collaborating with the prolific leaders of MSMC's GME program, primary investigators and EF Scholars that will help by focusing on research and residency training support.

Finding safer, more effective treatment options for all forms of disease is a primary focus of Mount Sinai Medical Center's mission. With over 700 physicians and 3700 employees it is the largest teaching hospital in all of South Florida.

The Everest Foundation is engaged in clinical research at various U.S. medical schools and ACGME teaching hospitals across the United States. It sponsors numerous collaborations nationally in various specialties from Internal Medicine, Physical Rehabilitative Medicine, General Surgery, Orthopedics and Psychiatry.

"We are all about helping GME programs getting better accreditation, better scholarly activity, and better patient care outcomes," says Mrs. Agata Everest, current CEO of the foundation that has partnerships from Los Angeles to Cleveland to New York. "We are always proud to be part of the excellent GME programs at wonderful institutions like Mt. Sinai Medical Center in Miami," she says, adding that the Everest Foundation looks forward to this new initiative growing and expanding in the years ahead.

If your organization, teaching hospital, medical school, or health system is interested in an alliance with The Everest Foundation, please visit their site at http://theeverestfoundation.org/ or call 310-477-7800.

*LOGO for media: Send2Press.com/mediaboom/16-1116s2p-everest-300dpi.jpg

The Everest Foundation (EF), a non-profit 501(c)(3) located in Los Angeles, California that is nationally focused on the advancement of medical research, has partnered with Mount Sinai Medical Center (MSMC) in Miami, Florida in a recent initiative to assist with research funding and Graduate Medical Education (GME) support.